ARWR ARROWHEAD PHARMACEUTICALS, INC.

Overview and Growth

Fiscal 2025 results for ARROWHEAD PHARMACEUTICALS, INC. combined $829.45M of revenue with net loss of $1.63M and an operating cash inflow of $179.55M. The $829.45M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Diluted earnings per share were -$0.01, translating the period’s attributable earnings into the amount reported for each diluted share. The company employed $1.39B of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 0.6x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

The reported operating result was $98.35M, capturing profitability after direct costs and the operating expenses reflected in the statements. Operating margin measured 11.9%, showing the portion of revenue preserved after the full set of operating costs. The company ended the period with a net loss of $1.63M, extending the operating result through all remaining items. The net loss equaled 0.2% of revenue, showing the bottom-line deficit relative to the company’s sales base. Pretax income was $51.53M, isolating the reported earnings outcome before the income-tax provision recognized for the fiscal year. Pretax income represented 6.2% of revenue, placing earnings before tax in the context of the company’s operating scale. The company recognized $21.42M of income tax for the period, completing the transition from pretax income to net income. Relative to pretax income, the tax provision measured 41.6%, quantifying the portion of pre-tax earnings paid in income tax. The net loss equaled 0.3% of period-end equity, showing the deficit relative to book capital. The loss-to-assets relationship was 0.1%, placing the bottom-line deficit against the company’s resource base. The net loss narrowed to $1.63M from $599.49M in fiscal 2024.

Liquidity and Capital Structure

At period end, the $1.39B asset base was financed through $881.88M of liabilities and $503.42M of equity. Current assets were $950.64M against $195.49M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered current liabilities by 4.86x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $226.55M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 115.9% of current liabilities, showing how much near-term coverage came from cash alone. Book equity represented 36.3% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 63.7% of total assets, quantifying the liability-funded share of the company’s resource base. Measured against total assets, cash and equivalents represented 16.4%, a balance-sheet composition measure rather than a liquidity forecast. Total assets were 21.5% higher than fiscal 2024 assets of $1.14B, measuring the company’s own balance-sheet change. Against $191.06M of equity in fiscal 2024, the current book-equity balance moved 163.5% and ended higher. Compared with $102.69M in fiscal 2024, the current cash balance moved 120.6% and finished higher.

Cash Flow and Earnings Quality

Operating activities produced a cash inflow of $179.55M, giving the cash-flow counterpart to the accrual-based profit measures reported for the year. The cash-flow statement records $22.67M of capital expenditures, the investment amount considered after operating cash generation. Relative to operating cash flow, capital expenditures measured 12.6%, connecting investment intensity with the company’s cash-generation base. After capital spending, free cash flow was $156.89M, leaving cash available for debt reduction, shareholder returns, or further investment. Relative to revenue, free cash flow equaled 18.9%, showing how much sales converted into cash after investment. Measured against total assets, free cash flow represented 11.3%, showing the cash productivity of the company’s assets.

Based on the annual report for the fiscal year ending Sep 30, 2025. Analysis generated Sep 24, 2026.